BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary. Gastroenterology. 2020;159:350-357. [PMID: 32283100 DOI: 10.1053/j.gastro.2020.04.012] [Cited by in Crossref: 106] [Cited by in F6Publishing: 93] [Article Influence: 53.0] [Reference Citation Analysis]
Number Citing Articles
1 Vechi HT, Maia LR, Alves MDM, Rodrigues-Neto JF. Favorable outcome of COVID-19 in a young woman with severe Crohn's disease on regular use of adalimumab and prednisone: a case report. Rev Inst Med Trop Sao Paulo 2020;62:e102. [PMID: 33331521 DOI: 10.1590/S1678-9946202062102] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Dudek P, Fabisiak A, Zatorski H, Malecka-Wojciesko E, Talar-Wojnarowska R. Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment. J Clin Med 2021;10:5660. [PMID: 34884361 DOI: 10.3390/jcm10235660] [Reference Citation Analysis]
4 Alhalabi M, Eddin KA, Ali F, Abbas A. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. Medicine (Baltimore) 2022;101:e28722. [PMID: 35089243 DOI: 10.1097/MD.0000000000028722] [Reference Citation Analysis]
5 Ricciuto A, Lamb CA, Benchimol EI, Walker GJ, Kennedy NA, Kuenzig ME, Kaplan GG, Kappelman MD, Ungaro RC, Colombel JF, Brenner EJ, Agrawal M, Reinisch W, Griffiths AM, Sebastian S. Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients. J Crohns Colitis 2021:jjab172. [PMID: 34570886 DOI: 10.1093/ecco-jcc/jjab172] [Reference Citation Analysis]
6 Rao A, Puertolas M, Runde J. COVID-19 and Gastrointestinal and Hepatobiliary Diseases. Pediatr Ann 2021;50:e315-9. [PMID: 34398713 DOI: 10.3928/19382359-20210721-02] [Reference Citation Analysis]
7 Queiroz NSF, Teixeira FV, Motta MP, Chebli LA, Hino AAF, Martins CA, Quaresma AB, Silva AAPD, Damião AOMC, Saad-Hossne R, Kotze PG. Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey. World J Gastroenterol 2021; 27(12): 1226-1239 [PMID: 33828396 DOI: 10.3748/wjg.v27.i12.1226] [Reference Citation Analysis]
8 Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
9 Sharma V, Shukla J, Suri V, Jena A, Mukerjee A, Mandavdhare HS, Bhalla A, Dutta U. Cost concerns, not the guidelines, drive clinical care of IBD during COVID pandemic in a resource limited setting. Expert Rev Gastroenterol Hepatol 2021;15:465-6. [PMID: 33576700 DOI: 10.1080/17474124.2021.1890583] [Reference Citation Analysis]
10 Zhang M, Bai X, Cao W, Ji J, Wang L, Yang Y, Yang H. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence. Front Immunol 2021;12:677957. [PMID: 34335579 DOI: 10.3389/fimmu.2021.677957] [Reference Citation Analysis]
11 Bernstein CN, Ng SC, Banerjee R, Steinwurz F, Shen B, Carbonnel F, Hamid S, Sood A, Yamamoto-Furusho JK, Griffiths A, Benchimol EI, Travis S, Lopes S, Rubin DT, Kaplan GG, Armstrong D, Gearry R; IBD-Emerging Nations Consortium and the WGO IBD Task Force on COVID-19. Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. Inflamm Bowel Dis 2021;27:836-47. [PMID: 32793973 DOI: 10.1093/ibd/izaa202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
12 Hashash JG, Jabak S, Francis FF, Regueiro M. Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy? Inflamm Bowel Dis. 2021;27:291-294. [PMID: 32619000 DOI: 10.1093/ibd/izaa173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ghoshal UC, Sahu S, Biswas SN, Singh P, Chaudhary M, Ghoshal U, Tiwari P, Rai S, Mishra SK. Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology. JGH Open 2021. [PMID: 33821221 DOI: 10.1002/jgh3.12498] [Reference Citation Analysis]
14 Siegel CA, Christensen B, Kornbluth A, Rosh JR, Kappelman MD, Ungaro RC, Johnson DF, Chapman S, Wohl DA, Mantzaris GJ. Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19. J Crohns Colitis. 2020;14:S769-S773. [PMID: 33085972 DOI: 10.1093/ecco-jcc/jjaa135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Bilal M, Sawhney MS, Feuerstein JD. Coronavirus disease-2019: implications for the gastroenterologist. Curr Opin Gastroenterol 2021;37:23-9. [PMID: 33074995 DOI: 10.1097/MOG.0000000000000694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Conti CB, Mainardi E, Soro S, Testa S, De Silvestri A, Drago A, Cereatti F, Grassia R. SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy. World J Gastrointest Endosc 2022; 14(3): 154-163 [DOI: 10.4253/wjge.v14.i3.154] [Reference Citation Analysis]
17 Barberio B, Buda A, Savarino EV. Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment? Gastroenterology 2021;160:2626-7. [PMID: 32877708 DOI: 10.1053/j.gastro.2020.08.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Oba J, Carvalho WB, Silva CA, Delgado AF. Gastrointestinal manifestations and nutritional therapy during COVID-19 pandemic: a practical guide for pediatricians. Einstein (Sao Paulo). 2020;18:eRW5774. [PMID: 32667418 DOI: 10.31744/einstein_journal/2020rw5774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Allez M, Fleshner P, Gearry R, Lakatos PL, Rubin DT. Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic. J Crohns Colitis. 2020;14:S774-S779. [PMID: 32722757 DOI: 10.1093/ecco-jcc/jjaa150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
20 Su S, Shen J, Zhu L, Qiu Y, He JS, Tan JY, Iacucci M, Ng SC, Ghosh S, Mao R, Liang J. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol 2020;13:1756284820934626. [PMID: 32595762 DOI: 10.1177/1756284820934626] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
21 Nakase H, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Wagatsuma K, Yokoyama Y, Hisamatsu T. Expert Opinions on the Current Therapeutic Management of Inflammatory Bowel Disease during the COVID-19 Pandemic: Japan IBD COVID-19 Taskforce, Intractable Diseases, the Health and Labor Sciences Research. Digestion. 2020;1-9. [PMID: 32892197 DOI: 10.1159/000510502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
22 Bekic D, Belosic Halle Z. Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations. Scand J Gastroenterol 2021;56:656-60. [PMID: 33765405 DOI: 10.1080/00365521.2021.1902561] [Reference Citation Analysis]
23 Kornbluth A, Kissous-Hunt M, George J, Legnani P. Management of Inflammatory Bowel Disease and COVID-19 in New York City 2020: The Epicenter of IBD in the First Epicenter of the Global Pandemic. Inflamm Bowel Dis. 2020;26:1779-1785. [PMID: 32879978 DOI: 10.1093/ibd/izaa212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 [DOI: 10.1101/2020.04.17.20069526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 de Franchis R. Digestive and Liver Diseases and the COVID-19 Pandemic. Dig Liver Dis 2020;52:799. [PMID: 32713475 DOI: 10.1016/j.dld.2020.07.006] [Reference Citation Analysis]
26 Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Celano R, Civitelli F, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Panceri R, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group. Dig Liver Dis. 2021;53:283-288. [PMID: 33388247 DOI: 10.1016/j.dld.2020.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Apostolou T, Koutroubakis IE, Manolakopoulos S, Mantzaris G, Rigopoulos D, Triantafyllou K, Vassilopoulos D. Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic. Mediterr J Rheumatol 2020;31:295-7. [PMID: 33196008 DOI: 10.31138/mjr.31.3.295] [Reference Citation Analysis]
28 Cohen RD, Feuerstein JD, Rubin DT. Reply. Gastroenterology 2021;160:2627. [PMID: 33561439 DOI: 10.1053/j.gastro.2021.02.012] [Reference Citation Analysis]
29 Weissman S, Aziz M, Smith WL, Elias S, Swaminath A, Feuerstein JD. Safety of biologics in inflammatory bowel disease patients with COVID-19. Int J Colorectal Dis 2021;36:2051-5. [PMID: 34131784 DOI: 10.1007/s00384-021-03977-9] [Reference Citation Analysis]
30 Colpo A, Astolfi L, Tison T, De Silvestro G, Marson P. Impact of COVID-19 pandemic in the activity of a Therapeutic Apheresis unit in Italy. Transfus Apher Sci 2020;59:102925. [PMID: 32912734 DOI: 10.1016/j.transci.2020.102925] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
31 Burke KE, Kochar B, Allegretti JR, Winter RW, Lochhead P, Khalili H, Colizzo FP, Hamilton MJ, Chan WW, Ananthakrishnan AN. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:155-61. [PMID: 33089863 DOI: 10.1093/ibd/izaa278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
32 Bourgonje AR, van Linschoten RCA, West RL, van Dijk MA, van Leer-Buter CC, Kats-Ugurlu G, Pierik MJ, Festen EAM, Weersma RK, Dijkstra G. Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. Therap Adv Gastroenterol 2021;14:17562848211012595. [PMID: 33995584 DOI: 10.1177/17562848211012595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Naseer M, Poola S, Dailey FE, Akin H, Tahan V. Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic. World J Meta-Anal 2020; 8(5): 383-399 [DOI: 10.13105/wjma.v8.i5.383] [Reference Citation Analysis]
34 Lees CW, Regueiro M, Mahadevan U; International Organization for the Study of Inflammatory Bowel Disease. Innovation in Inflammatory Bowel Disease Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease. Gastroenterology 2020;159:805-808.e1. [PMID: 32474119 DOI: 10.1053/j.gastro.2020.05.063] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
35 Conti CB, Mainardi E, Soro S, Testa S, De Silvestri A, Drago A, Cereatti F, Grassia R. SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy. World J Gastrointest Endosc 2022; 14(3): 153-162 [DOI: 10.4253/wjge.v14.i3.153] [Reference Citation Analysis]
36 Roy K, Agarwal S, Banerjee R, Paul MK, Purbey PK. COVID-19 and gut immunomodulation. World J Gastroenterol 2021; 27(46): 7925-7942 [DOI: 10.3748/wjg.v27.i46.7925] [Reference Citation Analysis]
37 Taneja V, El-Dallal M, Bilal M, Flier SN, Sheth SG, Ballou SK, Berzin TM, Pleskow DK, Feuerstein JD, Sawhney MS. Patient Perspective on Safety of Elective Gastrointestinal Endoscopy During the COVID-19 Pandemic. Tech Innov Gastrointest Endosc 2021;23:234-43. [PMID: 34007972 DOI: 10.1016/j.tige.2021.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Abu Baker A, Aljarrah Q, Eyadeh MA, Al-Muqbel K, Allouh MZ. A Periaortitis Patient Who Succumbed to COVID-19 While Undergoing Systemic Steroid Therapy: A Case Report and Literature Review. Am J Case Rep 2021;22:e932733. [PMID: 34415896 DOI: 10.12659/AJCR.932733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Reference Citation Analysis]
40 Niriella MA, De Silva AP, Liyanage KI, Sarin SK, de Silva HJ. COVID-19 and gastroenterology: clinical insights and recommendations for gastroenterology care providers. Scand J Gastroenterol 2020;55:1005-11. [PMID: 32650675 DOI: 10.1080/00365521.2020.1789896] [Reference Citation Analysis]
41 Renzo S, Scarallo L, Antoniello LM, Bramuzzo M, Chiaro A, Cisarò F, Contini ACI, De Angelis GL, Angelis PD, Nardo GD, Felici E, Iuliano S, Macchini F, Mantegazza C, Martelossi S, Oliva S, Parrinello F, Rea F, Pizzol A, Romano C, Russo G, Sansotta N, Lionetti P, Dabizzi E, Saccomani MD, Toma MD, Gatti S, Illiceto MT, Isoldi S, Maino M, Pellegrino M, Strisciuglio C. Impact of COVID-19 pandemic on pediatric endoscopy: a multicenter study on behalf of the SIGENP Endoscopy Working Group. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.02.010] [Reference Citation Analysis]
42 El-Dallal M, Saroufim A, Systrom H, Ballou S, Farhoud A, Pasam RT, Gadupudi SS, Osman K, Chaudrey K, Cheifetz A, Feuerstein JD. Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study. Scand J Gastroenterol 2021;:1-9. [PMID: 34894999 DOI: 10.1080/00365521.2021.2013527] [Reference Citation Analysis]
43 Grinevich VB, Gubonina IV, Doshchitsin VL, Kotovskaya YV, Kravchuk YA, Ped VI, Sas EI, Syrov AV, Tarasov AV, Tarzimanova AI, Tkacheva ON, Trukhan DI. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovasc Ther Prev 2020;19:2630. [DOI: 10.15829/1728-8800-2020-2630] [Cited by in Crossref: 26] [Cited by in F6Publishing: 3] [Article Influence: 13.0] [Reference Citation Analysis]
44 Dvornikova KA, Bystrova EY, Churilov LP, Lerner A. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep 2021;48:5745-58. [PMID: 34296352 DOI: 10.1007/s11033-021-06565-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Park YE, Lee YJ, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Kim SE, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement]. Korean J Gastroenterol 2021;78:105-16. [PMID: 34446633 DOI: 10.4166/kjg.2021.112] [Reference Citation Analysis]
46 Bhurwal A, Minacapelli CD, Orosz E, Gupta K, Tait C, Dalal I, Zhang C, Zhao E, Rustgi VK. COVID-19 status quo: Emphasis on gastrointestinal and liver manifestations . World J Gastroenterol 2021; 27(46): 7969-7981 [DOI: 10.3748/wjg.v27.i46.7969] [Reference Citation Analysis]
47 Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal manifestations in COVID-19. Trans R Soc Trop Med Hyg 2021:trab042. [PMID: 33728439 DOI: 10.1093/trstmh/trab042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Cao TT, Zhang GQ, Pellegrini E, Zhao Q, Li J, Luo LJ, Pan HQ. COVID-19 and its effects on the digestive system. World J Gastroenterol 2021; 27(24): 3502-3515 [PMID: 34239265 DOI: 10.3748/wjg.v27.i24.3502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Scribano ML. Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19? Dig Dis Sci. 2020;Online ahead of print. [PMID: 33073335 DOI: 10.1007/s10620-020-06624-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Grassia R, Soro S, Conti CB. Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not? Inflamm Bowel Dis 2020;26:e71. [PMID: 32386056 DOI: 10.1093/ibd/izaa110] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Quera R, Simian D, Flores L, Ibáñez P, Figueroa C. Impact of the COVID-19 pandemic on treatment adherence in patients with inflammatory bowel disease: Experience of a tertiary hospital in Chile. Gastroenterol Hepatol 2021;44:654-6. [PMID: 33232754 DOI: 10.1016/j.gastrohep.2020.10.014] [Reference Citation Analysis]
52 Rimondi A, Tontini GE, Mazza S, Caprioli F, Sangiovanni A, Lampertico P, Vecchi M. Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak. Inflamm Bowel Dis 2020;26:e128-9. [PMID: 32720979 DOI: 10.1093/ibd/izaa184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Okeke F, Mone A, Swaminath A. The Course of SARS-COV2 Infection Was Not Severe in a Crohn's Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection. Antibodies (Basel) 2020;9:E42. [PMID: 32824122 DOI: 10.3390/antib9030042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
54 Farkas K, Pigniczki D, Rutka M, Szántó KJ, Resál T, Bor R, Fábián A, Szepes Z, Lázár G, Molnár T. The complex relationship between viruses and inflammatory bowel disease - review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic. Therap Adv Gastroenterol 2021;14:1756284820988198. [PMID: 33953797 DOI: 10.1177/1756284820988198] [Reference Citation Analysis]
55 El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol 2021;37:313-9. [PMID: 33859104 DOI: 10.1097/MOG.0000000000000741] [Reference Citation Analysis]
56 Zingone F, Buda A, Savarino E. Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre. Dig Liver Dis 2020;52:1248-9. [PMID: 32811778 DOI: 10.1016/j.dld.2020.07.021] [Reference Citation Analysis]
57 Dhar J, Samanta J, Kochhar R. Corona Virus Disease-19 pandemic: The gastroenterologists' perspective. Indian J Gastroenterol. 2020;39:220-231. [PMID: 32783168 DOI: 10.1007/s12664-020-01075-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
58 Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, Jacob V, Battat R, Scherl E, Longman RS. No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD. Clin Gastroenterol Hepatol 2021;19:2312-2314.e3. [PMID: 34102340 DOI: 10.1016/j.cgh.2021.06.008] [Reference Citation Analysis]
59 Yin J, Ren Y, Yang K, Wang W, Wang T, Xiao W, Yang H. The role of hypoxia-inducible factor 1-alpha in inflammatory bowel disease. Cell Biol Int 2021. [PMID: 34658125 DOI: 10.1002/cbin.11712] [Reference Citation Analysis]
60 Saleem S, Ishtiaq R, Inayat F, Aziz M, Bleibel W. Gastrointestinal and Liver Manifestations in COVID-19 Population. Middle East J Dig Dis 2021;13:281-6. [DOI: 10.34172/mejdd.2021.236] [Reference Citation Analysis]
61 Di Ruscio M, Lunardi G, Buonfrate D, Gobbi F, Bertoli G, Piccoli D, Conti A, Geccherle A, Variola A. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy. Medicina (Kaunas) 2021;57:1048. [PMID: 34684085 DOI: 10.3390/medicina57101048] [Reference Citation Analysis]
62 Bossa F, Carparelli S, Latiano A, Palmieri O, Tavano F, Panza A, Pastore M, Marseglia A, D'Altilia M, Latiano T, Corritore G, Martino G, Nardella M, Guerra M, Terracciano F, Sacco M, Perri F, Andriulli A. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis. 2021;53:277-282. [PMID: 33423942 DOI: 10.1016/j.dld.2020.12.120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
63 Ramkissoon R, Wang XJ. The Impact of COVID-19 in Gastroenterology and Hepatology. J Clin Gastroenterol 2021;55:757-65. [PMID: 34420001 DOI: 10.1097/MCG.0000000000001600] [Reference Citation Analysis]
64 Zhang J, Garrett S, Sun J. Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. Genes Dis 2021;8:385-400. [PMID: 33521210 DOI: 10.1016/j.gendis.2020.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
65 Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A. Use of thiopurines in inflammatory bowel disease: an update. Intest Res 2022;20:11-30. [PMID: 33845546 DOI: 10.5217/ir.2020.00155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
66 Grover S, Bond SA, Mansour MK, Friedman S. Management of immunotherapy colitis: Special considerations in the COVID-19 era. Cancer 2020;126:4630-3. [PMID: 32797685 DOI: 10.1002/cncr.33125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Axelrad JE, Malter L, Hong S, Chang S, Bosworth B, Hudesman D. From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area. Inflamm Bowel Dis 2021;27:662-6. [PMID: 32578843 DOI: 10.1093/ibd/izaa162] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
68 Winthrop KL, Loftus EV, Baumgart DC, Reinisch W, Nduaka CI, Lawendy N, Chan G, Mundayat R, Friedman GS, Salese L, Thorpe AJ, Su C. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme. J Crohns Colitis 2021;15:914-29. [PMID: 33245746 DOI: 10.1093/ecco-jcc/jjaa233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Crespo J, Andrade R, Alberca de Las Parras F, Balaguer F, Barreiro-de Acosta M, Bujanda L, Gutiérrez A, Jorquera F, Iglesias-García J, Sánchez-Yagüe A, Calleja JL. Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. Gastroenterol Hepatol 2020;43:332-47. [PMID: 32409107 DOI: 10.1016/j.gastrohep.2020.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
70 Wu X, Lin J, Buch H, Ding Q, Zhang F, Cui B, Ji G. The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study. Front Public Health 2021;9:731578. [PMID: 34708016 DOI: 10.3389/fpubh.2021.731578] [Reference Citation Analysis]
71 Chen J, Peng X, Zhang M, Zhi M. Impact of Medication Discontinuation on Patients With Inflammatory Bowel Disease During the COVID-19 Outbreak.Gastroenterology. 2021;160:2223. [PMID: 32553758 DOI: 10.1053/j.gastro.2020.05.087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
72 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
73 Jena A, Singh AK, Kumar-M P, Sharma V, Sebastian S. Systematic review on failure to adhere to IBD therapies during the COVID-19 pandemic: Correct information is crucial. Dig Liver Dis 2020;52:1254-6. [PMID: 33011089 DOI: 10.1016/j.dld.2020.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Gupta S, Parker J, Smits S, Underwood J, Dolwani S. Persistent viral shedding of SARS-CoV-2 in faeces - a rapid review. Colorectal Dis. 2020;22:611-620. [PMID: 32418307 DOI: 10.1111/codi.15138] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 38.0] [Reference Citation Analysis]
75 Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV. Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. J Crohns Colitis 2020;14:S815-9. [PMID: 32520311 DOI: 10.1093/ecco-jcc/jjaa119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
76 Chela H, Pasha SB, Wan XF, Ghouri YA. A review on medical management of inflammatory bowel disease during the coronavirus disease 2019 pandemic. J Gastroenterol Hepatol. 2020. [PMID: 32876952 DOI: 10.1111/jgh.15241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
77 Di Ruscio M, Variola A, Angheben A, Resimini S, Geccherle A, Ruffo G, Barugola G. A Challenging Colectomy for Acute Severe Ulcerative Colitis Complicated by COVID-19. Inflamm Bowel Dis 2020;26:e120-2. [PMID: 32626898 DOI: 10.1093/ibd/izaa186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Navarro-Correal E, Borruel N, Robles V, Herrera-de Guise C, Mayorga Ayala LF, Pérez Martínez Z, Ibarz Casas A, Agustino Rodríguez S, Batuecas Duelt IJ, García Alcaide J, López Branchadell S, Zuriguel-Perez E, Casellas F. Impact of the COVID-19 pandemic on the activity of advanced-practice nurses on a reference unit for inflammatory bowel disease. Gastroenterol Hepatol 2021;44:481-8. [PMID: 33515625 DOI: 10.1016/j.gastrohep.2020.11.018] [Reference Citation Analysis]
79 Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:582291. [PMID: 33584261 DOI: 10.3389/fphar.2020.582291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2020;52:276-83. [PMID: 32359205 DOI: 10.1111/apt.15804] [Cited by in Crossref: 83] [Cited by in F6Publishing: 70] [Article Influence: 41.5] [Reference Citation Analysis]
81 Gajendran M, Perisetti A, Aziz M, Raghavapuram S, Bansal P, Tharian B, Goyal H. Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. Ann Gastroenterol. 2020;33:591-602. [PMID: 33162736 DOI: 10.20524/aog.2020.0547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
82 Sethi A, Swaminath A, Latorre M, Behin DS, Jodorkovsky D, Calo D, Aroniadis O, Mone A, Mendelsohn RB, Sharaiha RZ, Gonda TA, Khanna LG, Bucobo JC, Nagula S, Ho S, Carr-Locke DL, Robbins DH; New York Society for Gastrointestinal Endoscopy. Donning a New Approach to the Practice of Gastroenterology: Perspectives From the COVID-19 Pandemic Epicenter. Clin Gastroenterol Hepatol 2020;18:1673-81. [PMID: 32330565 DOI: 10.1016/j.cgh.2020.04.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
83 Viganò C, Mulinacci G, Palermo A, Barisani D, Pirola L, Fichera M, Invernizzi P, Massironi S. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World J Gastroenterol 2021; 27(33): 5520-5535 [PMID: 34588749 DOI: 10.3748/wjg.v27.i33.5520] [Reference Citation Analysis]
84 Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Civitelli F, Corsello A, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Giusti Z, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Nuti F, Panceri R, Rampado S, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Dig Liver Dis. 2021;53:183-189. [PMID: 33132063 DOI: 10.1016/j.dld.2020.10.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
85 El Kassas M, Abdelkader H, Medhat MA. COVID-19 in Egypt: Through crisis to adaptation; a gastroenterologist's perspective. Arab J Gastroenterol. 2020;21:207-210. [PMID: 32798187 DOI: 10.1016/j.ajg.2020.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Li J, Liu HH, Yin XD, Li CC, Wang J. COVID-19 illness and autoimmune diseases: recent insights. Inflamm Res 2021;70:407-28. [PMID: 33640999 DOI: 10.1007/s00011-021-01446-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Ahmed M. Coronavirus Disease 2019: A Gastroenterologist's Perspective in May 2020. Gastroenterology Res 2020;13:89-95. [PMID: 32655724 DOI: 10.14740/gr1292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Gilissen LPL, Heinen SGH, Rijpma-Jacobs L, Schoon E, Schreuder RM, Wensing AM, van der Ende-van Loon MCM, Bloemen JG, Stapelbroek JM, Stronkhorst A. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study. Clin Exp Med 2021. [PMID: 34542781 DOI: 10.1007/s10238-021-00755-3] [Reference Citation Analysis]
89 Xu F, Carlson SA, Wheaton AG, Greenlund KJ. COVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020. Inflamm Bowel Dis 2021;27:1166-9. [PMID: 33904584 DOI: 10.1093/ibd/izab041] [Reference Citation Analysis]
90 Kjeldsen J, Nielsen J, Ellingsen T, Knudsen T, Nielsen RG, Larsen MD, Lund K, Nørgård BM. Outcome of COVID-19 in hospitalized patients with chronic inflammatory diseases. A population based national register study in Denmark. J Autoimmun 2021;120:102632. [PMID: 33812171 DOI: 10.1016/j.jaut.2021.102632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
91 Shen B. Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic. Lancet Gastroenterol Hepatol 2021;6:254-5. [PMID: 33545082 DOI: 10.1016/S2468-1253(21)00009-1] [Reference Citation Analysis]
92 Brain O, Satsangi J. Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic. Gastroenterology 2021;160:1883-4. [PMID: 32553759 DOI: 10.1053/j.gastro.2020.05.083] [Reference Citation Analysis]
93 Amjad W, Haider R, Malik A, Qureshi W. Insights into the management of anorectal disease in the coronavirus 2019 disease era. Therap Adv Gastroenterol 2021;14:17562848211028117. [PMID: 34290826 DOI: 10.1177/17562848211028117] [Reference Citation Analysis]
94 Magro F, Nuzzo A, Abreu C, Libânio D, Rodriguez-Lago I, Pawlak K, Hollenbach M, Brouwer WP, Siau K. COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J 2021. [PMID: 34190413 DOI: 10.1002/ueg2.12115] [Reference Citation Analysis]
95 Sangha M, Roitman I, Sultan K, Swaminath A. SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares. Am J Gastroenterol 2021. [PMID: 34406140 DOI: 10.14309/ajg.0000000000001416] [Reference Citation Analysis]
96 Segal JP, Moss AC. Implications of recurrent SARS-CoV-2 outbreaks for IBD management. Frontline Gastroenterol 2021;12:316-21. [PMID: 34249317 DOI: 10.1136/flgastro-2020-101531] [Reference Citation Analysis]
97 Silva CA, Queiroz LB, Fonseca CB, Silva LEVD, Lourenço B, Marques HHS. Spotlight for healthy adolescents and adolescents with preexisting chronic diseases during the COVID-19 pandemic. Clinics (Sao Paulo) 2020;75:e1931. [PMID: 32401965 DOI: 10.6061/clinics/2020/e1931] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
98 Barlow-Pay F, Htut TW, Khezrian M, Myint PK. Systematic review of immunosuppressant guidelines in the COVID-19 pandemic. Ther Adv Drug Saf 2021;12:2042098620985687. [PMID: 33628418 DOI: 10.1177/2042098620985687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
99 Sultan S, Altayar O, Siddique SM, Davitkov P, Feuerstein JD, Lim JK, Falck-Ytter Y, El-Serag HB;  AGA Institute. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. 2020;159:320-334.e27. [PMID: 32407808 DOI: 10.1053/j.gastro.2020.05.001] [Cited by in Crossref: 145] [Cited by in F6Publishing: 143] [Article Influence: 72.5] [Reference Citation Analysis]
100 Anushiravani A, Vahedi H, Fakheri H, Mansour-Ghanaei F, Maleki I, Nasseri-Moghaddam S, Vosoghinia H, Ghadir MR, Hormati A, Aminisani N, Radmard AR, Khosravi B, Saberzadeh-Ardestani B, Malekzadeh M, Alatab S, Sadeghi A, Salahi S, Malekzadeh R, Sima AR. A Supporting System for Management of Patients with Inflammatory Bowel Disease during COVID-19 Outbreak: Iranian Experience-Study Protocol. Middle East J Dig Dis 2020;12:238-45. [PMID: 33564380 DOI: 10.34172/mejdd.2020.188] [Reference Citation Analysis]
101 Kamath C, Brenner EJ. The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic. Curr Res Pharmacol Drug Discov 2022;3:100101. [PMID: 35496814 DOI: 10.1016/j.crphar.2022.100101] [Reference Citation Analysis]
102 Viazis N, Pontas C, Manolakis A, Karampekos G, Tsoukali E, Galanopoulos M, Koustenis K, Archavlis E, Christidou A, Gazouli M, Mantzaris GJ. Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission. Acta Gastroenterol Belg 2021;84:423-8. [PMID: 34599566 DOI: 10.51821/84.3.007] [Reference Citation Analysis]
103 Sweed D, Abdelsameea E, Khalifa EA, Abdallah H, Moaz H, Moaz I, Abdelsattar S, Abdel-Rahman N, Mosbeh A, Elmahdy HA, Sweed E. SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore. Egypt Liver J 2021;11:64. [PMID: 34777871 DOI: 10.1186/s43066-021-00123-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D'Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris GJ, Papaconstantinou I, Katsanos K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert JP, Danese S, Fiorino G. Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. J Clin Med. 2020;9. [PMID: 33142843 DOI: 10.3390/jcm9113533] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
105 Feitosa MR, Parra RS, de Camargo HP, Ferreira SDC, Troncon LEA, da Rocha JJR, Féres O. COVID-19 quarantine measures are associated with negative social impacts and compromised follow-up care in patients with inflammatory bowel disease in Brazil. Ann Gastroenterol 2021;34:39-45. [PMID: 33414620 DOI: 10.20524/aog.2020.0558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Costrini NV. Clearing of the Clouds in Inflammatory Bowel Disease Management. Dig Dis Sci 2020;65:3411-7. [PMID: 33009978 DOI: 10.1007/s10620-020-06635-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Thng ZX, De Smet MD, Lee CS, Gupta V, Smith JR, McCluskey PJ, Thorne JE, Kempen JH, Zierhut M, Nguyen QD, Pavesio C, Agrawal R. COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. Br J Ophthalmol 2021;105:306-10. [PMID: 32532764 DOI: 10.1136/bjophthalmol-2020-316586] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
108 Bezzio C, Saibeni S. Severe Inflammatory Bowel Disease Flares and COVID-19: Expand the Gastroenterology-Surgery Team to Include an Infectious Disease Specialist. Gastroenterology 2021;160:2625-6. [PMID: 32553764 DOI: 10.1053/j.gastro.2020.05.082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
109 Fanlo P, Espinosa G, Adán A, Arnáez R, Fonollosa A, Heras H, Oteiza J, Del Carmelo Gracia Tello B, Sáez Comet L, Pallarés L. Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: Result of the COVID-19-GEAS patient survey. Arch Soc Esp Oftalmol (Engl Ed) 2021;96:347-52. [PMID: 34217471 DOI: 10.1016/j.oftale.2020.12.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Chen Y, Hu S, Wu H, Farraye FA, Bernstein CN, Zheng JJ, Kiran RP, Shen B. Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic. Lancet Gastroenterol Hepatol 2020;5:632-4. [PMID: 32411921 DOI: 10.1016/S2468-1253(20)30131-X] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
111 Sultan K, Mone A, Durbin L, Khuwaja S, Swaminath A. Review of inflammatory bowel disease and COVID-19. World J Gastroenterol 2020; 26(37): 5534-5542 [PMID: 33088153 DOI: 10.3748/wjg.v26.i37.5534] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
112 Sultan K, Durbin L, Bhardwaj R, Mackey J, Becher N, Abureesh M, Lakhani K, Mone A, Abergel J, Trindade A, Korelitz BI, Swaminath A. Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19. Gastroenterology Res 2021;14:324-33. [PMID: 35059066 DOI: 10.14740/gr1447] [Reference Citation Analysis]
113 Martin Arranz E, Suarez Ferrer C, García Ramírez L, Rueda García JL, Sánchez-Azofra M, Poza Cordón J, Noci J, Zabana Y, Barreiro-de Acosta M, Martín-Arranz MD. Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey. Inflamm Bowel Dis 2020;26:1149-54. [PMID: 32495826 DOI: 10.1093/ibd/izaa142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
114 Taxonera C, Alba C, Olivares D, Martin M, Ventero A, Cañas M. Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures. Inflamm Bowel Dis 2021;27:864-9. [PMID: 32812035 DOI: 10.1093/ibd/izaa223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
115 Fanlo P, Espinosa G, Adán A, Arnáez R, Fonollosa A, Heras H, Oteiza J, Del Carmelo Gracia Tello B, Comet LS, Pallarés L. Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: result of the COVID-19-GEAS patient survey. Arch Soc Esp Oftalmol 2021;96:347-52. [PMID: 33610384 DOI: 10.1016/j.oftal.2020.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Parigi TL, Bonifacio C, Danese S. Is It Crohn's Disease? Gastroenterology 2020;159:1244-6. [PMID: 32371110 DOI: 10.1053/j.gastro.2020.04.066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
117 Kennedy NA, Hansen R, Younge L, Mawdsley J, Beattie RM, Din S, Lamb CA, Smith PJ, Selinger C, Limdi J, Iqbal TH, Lobo A, Cooney R, Brain O, Gaya DR, Murray C, Pollok R, Kent A, Raine T, Bhala N, Lindsay JO, Irving PM, Lees CW, Sebastian S. Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterol 2020;11:343-50. [PMID: 32874484 DOI: 10.1136/flgastro-2020-101520] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
118 Marín-Jiménez I, Zabana Y, Rodríguez-Lago I, Marín L, Barreiro-de Acosta M, Esteve M; en representación de GETEII y GETECCU. COVID-19 and inflammatory bowel disease: questions arising from patient care and follow-up during the initial phase of the pandemic (February-April 2020). Gastroenterol Hepatol 2020;43:408-13. [PMID: 32419715 DOI: 10.1016/j.gastrohep.2020.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]